You are here

  • Home
  • Archive
  • Volume 9, Issue 5
  • TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor

Article metrics

Article menu

This article has a correction. Please see:

Download PDFPDF

XML
Immunotherapy biomarkers
Original research
TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor

 

Online download statistics by month:

Online download statistics by month: May 2021 to July 2025

AbstractFullPdf
May 2021394394103
Jun 202112012046
Jul 202112012035
Aug 202112512531
Sep 202117017045
Oct 202112312358
Nov 202110910841
Dec 2021818021
Jan 2022677526
Feb 2022959826
Mar 2022687853
Apr 2022596632
May 2022394017
Jun 2022465214
Jul 2022414411
Aug 2022353626
Sep 2022384320
Oct 2022424523
Nov 2022333312
Dec 2022393913
Jan 2023646426
Feb 2023515110
Mar 2023474917
Apr 2023111111
May 2023303014
Jun 2023252613
Jul 2023282820
Aug 202318195
Sep 202333338
Oct 202327277
Nov 202337376
Dec 2023383813
Jan 2024262719
Feb 2024282815
Mar 2024222275
Apr 2024313242
May 2024252517
Jun 2024282715
Jul 2024474918
Aug 2024353512
Sep 2024232412
Oct 2024343418
Nov 2024232417
Dec 2024555711
Jan 2025424319
Feb 20251351359
Mar 2025313117
Apr 2025434319
May 2025626340
Jun 2025272715
Jul 2025110
Total297130291193